作者: Sibylle Loibl , Carsten Denkert , Gunter von Minckwitz
DOI: 10.1016/J.BREAST.2015.07.018
关键词:
摘要: Abstract Neoadjuvant therapy is very often an adequate alternative to adjuvant therapy. This review summarizing the recent advances made in area of neoadjuvant breast cancer. The focus will lie on recently published clinical trials but not further highlight surgical, imaging and radiooncological issues related Recent findings Within last 1–1.5 years it has been discussed if treatment can be used as faster way get access new therapies, based data HER2+ cancer suggesting a higher pCR rate when dual anti-HER2 was used. Nevertheless this does necessarily translate always into better survival. In TNBC carboplatin could identified asset for patients, especially patients with gBRCA mutations. However, mature long term are still missing. approach ideal identify biomarkers which predict response or resistance given treatment. Tumour infiltrating lymphocytes PIK3CA mutations amongst most promising markers. Summary should considered all HER2-positive triple negative Clinical setting currently investigating approaches.